Please assess the completion status of the following clinical trial:

Trial Title: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed indolent B-cell non-Hodgkin lymphoma.~* Radiological measurable disease.~* Previous treatment for lymphoma is allowed, with the exception of use of bendamustine within 6 months or any prior use of vincristine sulfate liposome injection~* Eastern Cooperative Oncology Group performance status 0 or 1;~* Life expectancy of at least 6 months;~* Adequate organ and marrow function;~* Women of child-bearing potential and men must agree to use adequate contraception.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* History of allergic reactions attributed to any drug used in the study.~* Any lymphoma-directed therapy within 4 weeks.~* Any prior treatment with vincristine sulfate liposome injection.~* Prior treatment with bendamustine or vincristine sulfate within 180 days of enrollment.~* Patients who are receiving any other investigational agents with the exception of endocrine therapy for breast or prostate cancer.~* Central nervous system involvement.~* Peripheral sensory or motor neuropathy.~* History of a demyelinating condition.~* Positive test for the Human Anti-Chimeric Antibody (HACA).~* Patients receiving any medications or substances that are strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzyme are ineligible.~* Uncontrolled intercurrent illness.~* Prisoners.~* Pregnant or breast-feeding women.~* Known Human Immunodeficiency Virus (HIV) or active Hepatitis B infection~* Any prior or active cancer, which in the opinion of the investigator would preclude safe participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vincristine sulfate liposome injection 1.8 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 1.95 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 1.98 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 2.04 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 2.10 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 2.14 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 2.19 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 2.22 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
- Vincristine sulfate liposome injection 2.24 mg/m^2 (Type: EXPERIMENTAL): Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete